期刊文献+

NSCLC患者血清EGFR、VEGFA、VEGFR-2术前后变化及意义 被引量:2

Perioperative changes of serum levels of EGFR,VEGFA and VEGFR-2 in non-small cell lung cancer patients and the correlation between them
下载PDF
导出
摘要 目的探讨NSCLC患者手术前后血清中EGFR、VEGFA、VEGFR-2的变化及三者之间的关系。方法用ELISA方法检测38例NSCLC患者手术前后血清中EGFR、VEGFA、VEGFR-2的水平。结果 1.术前血清EGFR、VEGF-A、VEGFR-2水平与NSCLC患者的临床病理特征无相关性(P>0.05)。2.术后一天血清EGFR、VEGF-A、VEGFR-2水平高于术前水平。3.术前EGFR血清水平与VEGFR-2呈正相关,与VEGFA无相关性;术后EGFR水平与VEGFA、VEGFR-2之间均无相关性。结论 NSCLC患者术前血清EGFR、VEGF-A、VEGFR-2水平不能成为临床病理特征的分子标志。术前、后EGFR、VEGF-A、VEGFR-2的表达受不同途径的调节。 Objective To explore the perioperative changes of serum levels of EGFR,VEGFA and VEGFR-2 in patients with non-small cell lung cancer(NSCLC) and the correlation in all the three.Methods The perioperative serum concentrations of EGFR,VEGFA and V EGFR-2 were detected in 38 patients with NSCLC by ELISA method.Results 1.The preoperative serum concentrations of EGFR,VEGFA and VEGFR-2 in NSCLC(P〉0.05) had no correlations with patients′ clinicopathological features.2.The postoperative serum concentrations of EGFR,VEGFA and VEGFR-2 were higher than preoperative serum concentrations.3.The preoperative serum concentration of EGFR had a positive correlation with serum V EGFR-2 concentration,but no correlation with VEGFA concentration in NSCLC patients;The postoperative serum concentration of EGFR had no correlation with VFGFA or VEGFR-2.Conclusion The preoperative serum concentrations of EGFR,VEGFA and VEGFR-2 can not be looked as a molecular marker of patients′ clinicopathological features.The pre and post operative expressions of EGFR,VEGFA and VEGFR-2 maybe controlled by diffenrent pathways.
出处 《临床肺科杂志》 2011年第7期1062-1064,共3页 Journal of Clinical Pulmonary Medicine
基金 上海市卫生局科研课题项目(编号:054014)
关键词 非小细胞肺癌 表皮生长因子 血管内皮生长因子 酶联免疫吸附法 Carcinoma: Non-small cell lung Endothelial growth factor receptor Vascular endothelial growth factor Enzyme-linked immunosorbent assay
  • 相关文献

参考文献10

  • 1Roskoskir Jr.Vascular endothelial growth factor(VEGF) signaling in tumor progression[J].Cr it Rev Oncol Hema Tol,2007,62 (3):1792-213.
  • 2Enrique Carrillo de Santa Pau,Fernando Carrillo Arias,Enrique Caso Pelaez.Prognostic significance of the expression of vascular endothelial growth factors A,B,C,and D and their receptors R1,R2,and R3 in patients with non-small cell lung cancer[J].Cancer,2009,115:1701-12.
  • 3Ayd(l)n (C)iLEDA(G),Ak(l)n KAYA,(O)zkan YETKIN,et al.The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer(l)[J].Tüberküloz ve Toraks Dergisi,2008,56(4):390-395.
  • 4Y Lemos-Gonza lez,FJ Rodr(l) guez-Berrocal,OJ Cordero,et al.Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma[J].British Journal of Cancer,2007,96:1569-1578.
  • 5张志红,于敏,倪琛琛,陆友金.EGFR在非小细胞肺癌组织中的表达及其初步临床意义[J].临床肺科杂志,2010,15(8):1079-1081. 被引量:16
  • 6谢伟国,江莲,侯昕珩.外周血DNA EGFR基因CA-SSR多态与晚期非小细胞肺癌吉非替尼临床疗效的关系[J].临床肺科杂志,2010,15(7):973-975. 被引量:3
  • 7Chakra M,Pujol JL,Lamy PJ,et al.Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer[J].J Thorac Oncol,2008,3(10):1119-1126.
  • 8刘钊,周斌,赵坚,胡晔,朱昌生,张毅.VEGF-C和VEGFR-3在非小细胞肺癌癌组织及癌旁组织中的表达及意义[J].临床肺科杂志,2010,15(9):1217-1219. 被引量:7
  • 9张斌杰,张永奎,乐涵波,陈志军,王朝晔.非小细胞肺癌患者血清中VEGF动态变化规律的临床意义[J].临床肺科杂志,2008,13(10):1274-1275. 被引量:6
  • 10Pennell NA,Lynch TJ,JR.Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC[J].The Oncologist,2009,14:399-411.

二级参考文献34

  • 1区伟,吴一龙,戎铁华,谢丹,乔贵宾,王思愚,杨学宁.非小细胞肺癌组织芯片的EGFR免疫组化研究[J].肿瘤防治研究,2004,31(11):671-673. 被引量:4
  • 2张宏伟,张林,陈景寒,杜贾军.血管内皮生长因子和细胞黏附分子1在非小细胞肺癌组织中的表达[J].中华外科杂志,2005,43(6):354-357. 被引量:2
  • 3王勇,江丰收,孙玉蓓,胡冰.肺癌患者血清VEGF的表达及其临床意义[J].临床肺科杂志,2007,12(8):804-804. 被引量:12
  • 4Jorissen RN,Walker F,Pouliot N,et al.Epidermal growth factor receptor mechanisms of activation and signaling[J].Exp Cell Res,2003,284(1):31-53.
  • 5Fukuoka M,Yano S,Giaccone G,et al Multi-institutional randomized phaseⅡtrial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].Clin Oncol,2003,21(12):2237-2246.
  • 6Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,insymptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA,2003,290(16):2149-2158.
  • 7Lee DH,Han JY,Lee HG,et al.Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never smokers[J].Clin Cancer Res,2005,11(8):3032-3037.
  • 8van Puijenbroek R,Bosquee L,Meert AP,et al.Gefitinib monotherapy in advanced nonsmall cell lung cancer:a largeWestern community implementation study[J].Eur Respir J,2007,29(1):128-133.
  • 9Kalyn R.Overview of targeted therapies in oncology[J].Oncol Pharm Pract,2007,13(1):199-205.
  • 10Lynch TJ,Bell DW,Sordella R,et al.Activatingmutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.

共引文献27

同被引文献17

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部